BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lin J, Wu L, Bai X, Xie Y, Wang A, Zhang H, Yang X, Wan X, Lu X, Sang X, Zhao H. Combination treatment including targeted therapy for advanced hepatocellular carcinoma. Oncotarget 2016;7:71036-51. [PMID: 27626176 DOI: 10.18632/oncotarget.11954] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Lin J, Zhao S, Wang D, Song Y, Che Y, Yang X, Mao J, Xie F, Long J, Bai Y, Yang X, Zhang L, Bian J, Lu X, Sang X, Pan J, Wang K, Zhao H. Targeted Next-Generation Sequencing Combined With Circulating-Free DNA Deciphers Spatial Heterogeneity of Resected Multifocal Hepatocellular Carcinoma. Front Immunol 2021;12:673248. [PMID: 34211467 DOI: 10.3389/fimmu.2021.673248] [Reference Citation Analysis]
2 Li C, Liu JY, Peng W, Wen TF, Yan LN, Yang JY, Li B, Wang WT, Xu MQ. Liver resection versus transplantation for multiple hepatocellular carcinoma: a propensity score analysis. Oncotarget 2017;8:81492-500. [PMID: 29113408 DOI: 10.18632/oncotarget.20623] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
3 Zhou ZQ, Zhao JJ, Chen CL, Liu Y, Zeng JX, Wu ZR, Tang Y, Zhu Q, Weng DS, Xia JC. HUS1 checkpoint clamp component (HUS1) is a potential tumor suppressor in primary hepatocellular carcinoma. Mol Carcinog 2019;58:76-87. [PMID: 30182378 DOI: 10.1002/mc.22908] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
4 Chen J, Liu J, Xu B, Cao Y, Liang X, Wu F, Shen X, Ma X, Liu J. Ethoxy-erianin phosphate and afatinib synergistically inhibit liver tumor growth and angiogenesis via regulating VEGF and EGFR signaling pathways. Toxicol Appl Pharmacol 2022;:115911. [PMID: 35143806 DOI: 10.1016/j.taap.2022.115911] [Reference Citation Analysis]
5 Tong Y, Wang M, Huang H, Zhang J, Huang Y, Chen Y, Pan H. Inhibitory effects of genistein in combination with gefitinib on the hepatocellular carcinoma Hep3B cell line. Exp Ther Med 2019;18:3793-800. [PMID: 31611933 DOI: 10.3892/etm.2019.8027] [Reference Citation Analysis]
6 Abdel-hamid NM, Abass SA, Eldomany RA, Abdel-kareem MA, Zakaria S. Dual regulating of mitochondrial fusion and Timp-3 by leflunomide and diallyl disulfide combination suppresses diethylnitrosamine-induced hepatocellular tumorigenesis in rats. Life Sciences 2022;294:120369. [DOI: 10.1016/j.lfs.2022.120369] [Reference Citation Analysis]
7 Korean Liver Cancer Association., National Cancer Center. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut Liver 2019;13:227-99. [PMID: 31060120 DOI: 10.5009/gnl19024] [Cited by in Crossref: 90] [Cited by in F6Publishing: 90] [Article Influence: 45.0] [Reference Citation Analysis]
8 Wang P, Shen Y, Zhao L. Chitosan nanoparticles loaded with aspirin and 5-fluororacil enable synergistic antitumour activity through the modulation of NF-κB/COX-2 signalling pathway. IET Nanobiotechnol 2020;14:479-84. [PMID: 32755957 DOI: 10.1049/iet-nbt.2020.0002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
9 Liu W, Tu W, Li L, Liu Y, Wang S, Li L, Tao H, He H. Revisiting Connectivity Map from a gene co-expression network analysis. Exp Ther Med 2018;16:493-500. [PMID: 30112021 DOI: 10.3892/etm.2018.6275] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
10 Sikimić V, Herud-sikimić O. Modelling efficient team structures in biology. Journal of Logic and Computation 2022. [DOI: 10.1093/logcom/exac021] [Reference Citation Analysis]
11 Singh AK, Bhadauria AS, Kumar U, Raj V, Rai A, Kumar P, Keshari AK, Kumar D, Maity B, Nath S, Prakash A, Saha S. Novel Indole-fused benzo-oxazepines (IFBOs) inhibit invasion of hepatocellular carcinoma by targeting IL-6 mediated JAK2/STAT3 oncogenic signals. Sci Rep 2018;8:5932. [PMID: 29651140 DOI: 10.1038/s41598-018-24288-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
12 Sarfraz M, Afzal A, Raza SM, Bashir S, Madni A, Khan MW, Ma X, Xiang G. Liposomal co-delivered oleanolic acid attenuates doxorubicin-induced multi-organ toxicity in hepatocellular carcinoma. Oncotarget 2017;8:47136-53. [PMID: 28525367 DOI: 10.18632/oncotarget.17559] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
13 Leng S, Yang M, Zhao Y, Zhao J, Zeng Z, Yang Y, Yuan J, Lv B, Jun F, Wang B. PTIP promotes recurrence and metastasis of hepatocellular carcinoma by regulating epithelial-mesenchymal transition. Oncotarget 2017;8:58184-98. [PMID: 28938547 DOI: 10.18632/oncotarget.16436] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
14 Shi BM, Lu W, Ji K, Wang YF, Xiao S, Wang XY. Study on the value of serum miR-106b for the early diagnosis of hepatocellular carcinoma. World J Gastroenterol 2017; 23(20): 3713-3720 [PMID: 28611524 DOI: 10.3748/wjg.v23.i20.3713] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
15 Kumar P, Agarwal A, Singh AK, Gautam AK, Chakraborti S, Kumar U, Kumar D, Bhattacharya B, Panda P, Saha B, Qidwai T, Maity B, Saha S. Antineoplastic properties of zafirlukast against hepatocellular carcinoma via activation of mitochondrial mediated apoptosis. Regulatory Toxicology and Pharmacology 2019;109:104489. [DOI: 10.1016/j.yrtph.2019.104489] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
16 Liang HW, Ye ZH, Yin SY, Mo WJ, Wang HL, Zhao JC, Liang GM, Feng ZB, Chen G, Luo DZ. A comprehensive insight into the clinicopathologic significance of miR-144-3p in hepatocellular carcinoma. Onco Targets Ther 2017;10:3405-19. [PMID: 28744145 DOI: 10.2147/OTT.S138143] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
17 Sun Y, Ma W, Yang Y, He M, Li A, Bai L, Yu B, Yu Z. Cancer nanotechnology: Enhancing tumor cell response to chemotherapy for hepatocellular carcinoma therapy. Asian J Pharm Sci 2019;14:581-94. [PMID: 32104485 DOI: 10.1016/j.ajps.2019.04.005] [Cited by in Crossref: 65] [Cited by in F6Publishing: 49] [Article Influence: 21.7] [Reference Citation Analysis]
18 Huang B, Mu P, Yu Y, Zhu W, Jiang T, Deng R, Feng G, Wen J, Zhu X, Deng Y. Inhibition of EZH2 and activation of ERRγ synergistically suppresses gastric cancer by inhibiting FOXM1 signaling pathway. Gastric Cancer 2021;24:72-84. [PMID: 32529327 DOI: 10.1007/s10120-020-01097-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Xiong Q, Cui M, Yu G, Wang J, Song T. Facile Fabrication of Reduction-Responsive Supramolecular Nanoassemblies for Co-delivery of Doxorubicin and Sorafenib toward Hepatoma Cells. Front Pharmacol 2018;9:61. [PMID: 29487523 DOI: 10.3389/fphar.2018.00061] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
20 Woo SM, Seo SU, Kim SH, Nam JO, Kim S, Park JW, Min KJ, Kwon TK. Hispidulin Enhances TRAIL-Mediated Apoptosis via CaMKK/AMPK/USP51 Axis-Mediated Bim Stabilization. Cancers (Basel) 2019;11:E1960. [PMID: 31817696 DOI: 10.3390/cancers11121960] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
21 Duan X, Li H, Wang M, Ju S, Li F, Chen P, Lu H, Han X, Ren J. PSMC2/ITGA6 axis plays critical role in the development and progression of hepatocellular carcinoma. Cell Death Discov 2021;7:217. [PMID: 34413286 DOI: 10.1038/s41420-021-00585-y] [Reference Citation Analysis]
22 Ma L, Tao C, Zhang Y, Abdulhay E. MicroRNA-517c Functions as a Tumor Suppressor in Hepatocellular Carcinoma via Downregulation of KPNA2 and Inhibition of PI3K/AKT Pathway. Journal of Healthcare Engineering 2022;2022:1-9. [DOI: 10.1155/2022/7026174] [Reference Citation Analysis]
23 Zhou XT, Pu ZJ, Liu LX, Li GP, Feng JL, Zhu HC, Wu LF. Inhibition of autophagy enhances adenosine‑induced apoptosis in human hepatoblastoma HepG2 cells. Oncol Rep 2019;41:829-38. [PMID: 30535464 DOI: 10.3892/or.2018.6899] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
24 Zhang L, Li G. Comment on "combination treatment including targeted therapy for advanced hepatocellular carcinoma". Hepatobiliary Surg Nutr 2016;5:444-6. [PMID: 27826561 DOI: 10.21037/hbsn.2016.10.01] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]